WO2001074390A2 - The use of a calcium channel blocker for treating renal disorders - Google Patents

The use of a calcium channel blocker for treating renal disorders Download PDF

Info

Publication number
WO2001074390A2
WO2001074390A2 PCT/IB2001/000518 IB0100518W WO0174390A2 WO 2001074390 A2 WO2001074390 A2 WO 2001074390A2 IB 0100518 W IB0100518 W IB 0100518W WO 0174390 A2 WO0174390 A2 WO 0174390A2
Authority
WO
WIPO (PCT)
Prior art keywords
calcium channel
amlodipine
channel blocker
treatment
agent
Prior art date
Application number
PCT/IB2001/000518
Other languages
French (fr)
Other versions
WO2001074390A3 (en
Inventor
Adrian Paul Foster
Original Assignee
Pfizer Limited
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Limited, Pfizer Inc. filed Critical Pfizer Limited
Priority to MXPA02009819A priority Critical patent/MXPA02009819A/en
Priority to BR0109783-0A priority patent/BR0109783A/en
Priority to EP01914134A priority patent/EP1284719A2/en
Priority to JP2001572132A priority patent/JP2003528927A/en
Priority to CA002403950A priority patent/CA2403950A1/en
Priority to AU2001239510A priority patent/AU2001239510A1/en
Publication of WO2001074390A2 publication Critical patent/WO2001074390A2/en
Publication of WO2001074390A3 publication Critical patent/WO2001074390A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals

Definitions

  • This invention relates to the treatment of renal disease in animals, especially chronic renal failure.
  • Renal disease including renal failure (acute and chronic) is a common clinical problem which tends to increase with the age of animals (including humans). Conditions are described in "The Merck Manual", 16th edition, ch.149, pp.1661, 1665 (Merck Research Laboratories (1992), and are commonly, but not always, associated with abnormally high blood pressure (hypertension). Renal disease often results in long suffering periods where the patient endures uncomfortable and painful symptoms, often involving injury to eyes, heart and brain. Dialysis and kidney transplantation can be used as treatments if circumstances allow, but these procedures can have serious complications, including, for transplantation, organ rejection.
  • Amlodipine disclosed in EP 0 089 167, etc., is a dihydropyridine calcium channel blocker which is licensed for use as an antihypertensive and antianginal agent. It is sold as the besylate salt (disclosed in EP 0 244 944, etc.) in 2.5mg, 5mg and 10mg dosages under the trade names Norvasc, Norvas, Istin, Amlor, etc. by Pfizer Inc. and related companies. Both of these publications are herein incorporated by reference.
  • calcium channel blockers such as amlodipine (e.g. as the besylate salt) can be used to treat renal disease in animals which are not hypertensive, i.e. animals which are "normotensive".
  • Normal means having systemic arterial blood pressure values within normal or reference ranges established for the animal species of interest, using acceptable methods for measuring such blood pressure under appropriate circumstances, and below generally accepted “hypertensive” ranges for such animals.
  • reference range values may be established for representative subclasses, races, breeds, etc. (e.g. humans, lab. animals, specific subpopulations, etc.).
  • renal disease in normotensive patients especially normotensive companion animals such as cats
  • a calcium channel blocker such as amlodipine
  • An aspect of the current invention is the treatment of renal disease in normotensive animals with a calcium channel blocker.
  • the animal is a mammal.
  • a preferred mammal is a human.
  • Another preferred group of mammals are companion animals such as horses, and domestic cats and dogs.
  • the most preferred companion animal is a domestic cat.
  • the renal disease is chronic renal failure.
  • the calcium channel blocker is a dihydropyridine calcium channel blocker such as amlodipine, nifedipine, nitrendipine, nimodipine, nicardipine, felodipine, etc.
  • the calcium channel blocker can be present as a pharmaceutically acceptable salt or solvate thereof.
  • Pharmaceutically acceptable salts and solvates are non-toxic to the species being treated.
  • Suitable pharmaceutically acceptable salts for dihydropyridine calcium channel blockers include acid addition salts such as the hydrochloride, hydrobromide, hydroiodide, bisulphate, acid citrate, bitartrate, ethansulphonate, sulphate, phosphate or acid phosphate, acetate, maleate, fumarate, lactate, tartrate, citrate, gluconate, benzenesulphonate (besylate), p-toluenesulphonate (tosylate), methanesulphonate (mesylate), succinate, salicylate, nitrate, etc.
  • the calcium channel blocker is amlodipine and the pharmaceutically acceptable salts thereof, including acid addition salts such as the hydrochloride, hydrobromide, hydroiodide, bisulphate, acid citrate, bitartrate, ethansulphonate, sulphate, phosphate or acid phosphate, acetate, maleate, fumarate, lactate, tartrate, citrate, gluconate, benzenesulphonate (besylate), p-toluenesulphonate (tosylate), methanesulphonate (mesylate), succinate, salicylate, nitrate, etc.
  • acid addition salts such as the hydrochloride, hydrobromide, hydroiodide, bisulphate, acid citrate, bitartrate, ethansulphonate, sulphate, phosphate or acid phosphate, acetate, maleate, fumarate, lactate, tartrate, citrate, gluconate, benzenesulphonate (
  • amlodipine besylate salt Most preferred is the amlodipine besylate salt.
  • Treatment refers to prevention, alleviation and/or cure of the condition.
  • Another aspect of the invention is the administration, to a normotensive animal, of an efficacious amount of a calcium channel blocker, such as between 0.01 to 3mg/kg, preferably between 0.1mg/kg and 0.3mg/kg, more preferably between 0.12 and 0.25 mg/kg, amlodipine (preferably administered as the besylate salt) of the animal to treat renal disease such as chronic renal failure.
  • a calcium channel blocker such as between 0.01 to 3mg/kg, preferably between 0.1mg/kg and 0.3mg/kg, more preferably between 0.12 and 0.25 mg/kg
  • amlodipine preferably administered as the besylate salt
  • amlodipine which comprises about 0.1-1.5 mg, preferably about 0.2-0.6, or about 0.8 to 1.5 mg, most preferably about 0.1 , 0.2, 0.4, 0.6, 0.8, 1.0, 1.2 or 1.5mg amlodipine per unit, where amlodipine is preferably present as its besylate salt, suitable for, or adapted for, the treatment of normotensive cats with renal disease, such as chronic renal failure.
  • unit doses can also be used to treat-renal disease in animals with hypertension.
  • the calcium channel blocker can be administered / formulated with an antihypertensive agent of a different class (i.e.
  • Suitable agents include angiotensin converting enzyme (ACE) inhibitors such as those licensed for use in treating hypertension, such as benazepril, benazeprilat, captopril, enalapril, enalaprilat, fosinopril sodium, lisinopril, pentopril, perindopril, quinapril hydrochloride, quinaprilat, ramipril. ramiprilat, trandolapril, zofenopril calcium, and the like.
  • ACE angiotensin converting enzyme
  • co-administration may take place in a number of different ways, including: the active agents may be present in the same dosage form for single administration; the active agents may be administered in separate dosage forms, by the same or different administration routes, and at the same, substantially the same or at different times.
  • a suitable ACE inhibitor for co-administration in the treatment of renal disease is thought to be benazepril, currently marketed as FortekorTM, which for cats is administered at about 0.5 to about 1 mg/kg per day for cats as a 2.5mg or 5mg dose.
  • the calcium channel blockers can be administered alone but will generally be administered in admixture with a suitable pharmaceutical excipient, diluent or carrier selected with regard to the intended route of administration and standard pharmaceutical or veterinary practice.
  • a suitable pharmaceutical excipient, diluent or carrier selected with regard to the intended route of administration and standard pharmaceutical or veterinary practice.
  • suitable pharmaceutical carriers, excipents, diluents, etc. can be found in Remington's Pharmaceutical Science, A. Osol, a standard reference text in the field.
  • the calcium channel blocker (and/or other active agents) can be administered orally, buccally or sublingually in the form of tablets, capsules, ovules, elixirs, syrups, boluses, powders, pastes, drenches , medicated food or drinking water or other liquid, solutions or suspensions, which may contain flavouring or colouring agents, for immediate-, delayed-, modified-, sustained-, pulsed- or controlled-release applications.
  • Such tablets may contain excipients such as microcrystalline cellulose, silicified microcrystalline cellulose, lactose, sodium citrate, calcium carbonate, dibasic calcium phosphate and glycine, disintegrants such as starch (optionally pre-gelatinised, preferably corn, potato or tapioca starch), sodium starch glycollate, croscarmellose sodium and certain complex silicates, and granulation binders such as polyvinylpyrrolidone, hydroxypropylmethylcellulose (HPMC), hydroxypropylcellulose (HPC), sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, stearic acid, glyceryl behenate and talc may be included.
  • excipients such as microcrystalline cellulose, silicified microcrystalline cellulose, lactose, sodium citrate, calcium carbonate, dibasic calcium phosphate and glycine
  • disintegrants such as starch (optionally pre-gelatinised, preferably corn
  • cyclodextrin solublity modifiers may be included. Additionally antioxidants may be included. Agents to improve palatability, such as flavouring agents (e.g. yeast, yeast extract, pork liver) may also be included.
  • flavouring agents e.g. yeast, yeast extract, pork liver
  • the agents apart from the calcium channel blocker may be present in intimate mixture with the calcium channel blocker, or they may be separated, e.g. in a bilayer, trilayer or other multlayer tablet or coated tablet, or a microparticulate capsule.
  • Solid compositions of a similar type may also be employed as fillers in gelatin capsules.
  • Preferred excipients in this regard include lactose, starch, a cellulose, milk sugar or high molecular weight polyethylene glycols.
  • the calcium channel blockers (and/or other active agents) may be combined with various sweetening or flavouring agents, colouring matter or dyes, with emulsifying and/or suspending agents and with diluents such as water, ethanol, propylene glycol and glycerin, and combinations thereof.
  • the calcium channel blockers can also be administered parenterally, for example, intravenously, intra-arterially, intraperitoneally, intrathecally, intraventricularly, intraurethrally, intrasternally, intracranially, intramuscularly or subcutaneously, or they may be administered by infusion techniques.
  • parenteral administration they are best used in the form of a sterile aqueous solution, or sterile aqueous or oil suspension, which may contain other substances, for example, enough salts or glucose to make the solution isotonic with blood.
  • the aqueous solutions should be suitably buffered (preferably to a pH of from 3 to 9), if necessary.
  • the preparation of suitable parenteral formulations under sterile conditions is readily accomplished by standard pharmaceutical techniques well-known to those skilled in the art.
  • the calcium channel blockers can also be administered intranasally or by inhalation and are conveniently delivered in the form of a dry powder inhaler or an aerosol spray presentation from a pressurised container, pump, spray or nebuliser with the use of a suitable propellant, e.g.
  • the dosage unit may be determined by providing a valve to deliver a metered amount.
  • the pressurised container, pump, spray or nebuliser may contain a solution or suspension of the active compound, e.g.
  • Capsules and cartridges (made, for example, from gelatin) for use in an inhaler or insufflator may be formulated to contain a powder mix of the compound and a suitable powder base such as lactose or starch.
  • the calcium channel blocker (and/or other active agents) can be administered in the form of a suppository or pessary, or may be applied topically in the form of a gel, a pour-on, spot-on, dip, spray, mousse, shampoo, collar or powder formulation, ear tag, hydrogel, lotion, solution, cream, gel, paste, patch, ointment or dusting powder.
  • the calcium channel blockers (and/or other active agents) may also be dermally or transdermally administered, for example, by the use of a skin patch. They may also be administered by the pulmonary or rectal routes.
  • the calcium channel blocker (and/or other active agents) can be formulated as a suitable ointment containing the active compound suspended or dissolved in, for example, a mixture with one or more of the following: mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene polyoxypropylene compound, emulsifying wax and water.
  • ком ⁇ онентs can be formulated as a suitable lotion or cream, suspended or dissolved in, for example, a mixture of one or more of the following: mineral oil, sorbitan monostearate, a polyethylene glycol, liquid paraffin, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2- octyldodecanol, benzyl alcohol and water.
  • the compounds may be administered with the animal feedstuff and for this purpose a concentrated feed additive or premix may be prepared for mixing with the normal animal feed.
  • an oral formulation for a medicament comprising: a solid masticable portion and one or more reservoir portions encompassed by said solid masticable portion; the solid masticable portion consisting of a fully edible material, having a Young's modulus of 0.01-5MPa, and compressive strength in the range 10- 10,000 mJ, the reservoir portion or portions comprising a releasable dose of the medicament in a fluid (preferably a liquid) form, with a viscosity below 800mPa.s at body temperature (ca. 36-ca.40°C), such that on mastication, the masticable portion is ruptured and the unit dose of the medicament is released in a short space of time from the reservoir portion into the oral cavity.
  • the calcium channel blockers (and/or other active agents mentioned above) can also be administered together with yet further active agents should the medical need arise.
  • the physician or veterinarian in any event will determine the actual dosage which will be most suitable for any individual patient and it will vary with the age, weight and response of the particular patient.
  • the dosages mentioned herein are exemplary of the average case. There can, of course, be individual instances where higher or lower dosage ranges are merited and such are within the scope of this invention.
  • the skilled person will appreciate that, in the treatment of certain conditions the compounds may be taken as a single or multiple dose as needed or desired.
  • the route of administration will depend on a number of factors, and in accordance with standard medical and veterinary practice, including the species of animal to be treated, size of the animal, ease of administration, etc. Based on the results disclosed herein, the envisioned dosage regime for amlodipine in the treatment of renal disease, such as chronic renal failure, in normotensive animals, is 0.125-0.25mg/kg/day.
  • amlodipine dosage regime is 0.125 - 0.25 mg/kg / day, which translates to 0.4mg/cat/day for cats weighing from 1.6kg up to about 3kg, 0.8mg/cat/day for cats weighing between 3-6.5kg, and 1.2mg/cat/day for cats weighing about 6.5-9.5kg. Cats falling outside these weight ranges will of course be treatable in proportion to their weight.
  • Oral administration is preferred, preferably of a tablet.
  • Benazepril may be co-administered at 0.5 to 1 mg/kg per day, e.g. as a 2.5mg or 5mg dose for domestic cats (as in FortekorTM mentioned above).
  • Other ACE inhibitors and/or endothelin-reducing agents may be co- administered with the calcium channel blocker such as amlodipine according to the medical need, efficacy, etc.
  • the efficacy of calcium channel blockers such as amlodipine in the treatment of chronic renal failure, in the dosages mentioned and with the populations mentioned can be demonstrated by measurement of renal function (e.g. by GFR measurements or any other measurements known in the art such as renal plasma flow using appropriate markers such as creatinine, inulin, iohexol, radioisotopes and other validated markers of dynamic renal function, urine concentrations of analytes such as protein and/or protein indexed to urine creatinine concentration, etc.). Measurements can be made before treatment, during treatment and after treatment by methods well-known in the art. For control purposes, a similar population can be treated with a placebo instead of a calcium channel blocker.
  • GFR measurements or any other measurements known in the art such as renal plasma flow using appropriate markers such as creatinine, inulin, iohexol, radioisotopes and other validated markers of dynamic renal function, urine concentrations of analytes such as protein and/or protein indexed to urine creatinine concentration, etc
  • Amlodipine besylate at ca. 0.125 mg/kg to ca. 0.25 mg/kg was administered orally by tablet (0.2 mg, 0.4 mg, 0.8 mg and 1.2mg) to normotensive cats (systolic blood pressure of 160mm Hg or less as measured under standard conditions) once daily for a number of weeks, and measurements made at intervals to measure the effect on kidney function in cats presented as veterinary patients with renal problems.
  • a number of cats were treated with an oral placebo tablet.
  • Various breeds and crossbreeds of cats of approximately 6 months of age or older were used in the trial. Initial weights of 0.8kg to 9.6 kg were chosen, and the cats were either males or non-pregnant females (entire or neutered). For each animal, the body weight was used to select the appropriate tablet potency of amlodipine (0.125 to 0.25 mg/kg/day) according to the following table:
  • amlodipine tablets used in the study were complemented by placebo tablets with the same excipients and which had the same dimensions and appearance.
  • amlodipine besylate tablets used had the following compositions:
  • the tablets were prepared using standard blending and direct compression techniques.
  • the tablets described herein used the same excipients and manufacturing processes as the commercially available tablets.
  • Chronic renal failure is generally considered an irreversible and progressive disease in cats.
  • Chronic renal failure was diagnosed in each cat in this study.
  • Cats were considered normotensive as defined by systolic arterial blood pressure less than 160 mm Hg prior to the onset of treatment.
  • Cats were randomly assigned to treatment with either amlodipine besylate tablets at 0.125 to 0.25 mg/kg (as described above) or placebo tablets administered once daily by the oral route.
  • Renal function was assessed by determining glomerular filtration rate (GFR).
  • GFR glomerular filtration rate was estimated from plasma clearance of the exogenous marker, iohexol, approximately 7 days prior to the onset of treatment (day -7) and on approximately days 28, 56, 112, and 224 following onset of treatment.

Abstract

The invention described herein relates to the use of calcium channel blockers such as amlodipine in the treatment of renal disease in normotensive animals. Also described are new unit doses of amlodipine suitable for the treatment of renal disease in normotensive cats.

Description

TREATMENT OF RENAL DISORDERS
This invention relates to the treatment of renal disease in animals, especially chronic renal failure.
Renal disease, including renal failure (acute and chronic) is a common clinical problem which tends to increase with the age of animals (including humans). Conditions are described in "The Merck Manual", 16th edition, ch.149, pp.1661, 1665 (Merck Research Laboratories (1992), and are commonly, but not always, associated with abnormally high blood pressure (hypertension). Renal disease often results in long suffering periods where the patient endures uncomfortable and painful symptoms, often involving injury to eyes, heart and brain. Dialysis and kidney transplantation can be used as treatments if circumstances allow, but these procedures can have serious complications, including, for transplantation, organ rejection.
In animals the underlying aetiology of the disease can be uncertain, even when histopathological examination has taken place (see e.g. J.Elliott and PJ Barber, J.Small Animal Practice (Feb 1998) vol.39, 78; AR Michell, VetAnnual (1995) 35: 159).
There are many commonly used measurements of renal function such as those mentioned by DR Finco et al, in J Vet Intern Med (1999) 13:516-528 - glόmerular filtration rate (GFR), plasma creatinine concentration, morphologic examination of kidney tissue, blood urea nitrogen, incidental biological events such as hypertension and proteinurea. Michell (supra) defines chronic renal failure as a "failure of clearance". Finco (supra) suggests that declining GFR measurements are the most reliable indicator of the disease. Treatment of renal disease associated with hypertension with antihypertensive agents has been propounded, for example with angiotensin converting enzyme (ACE) inhibitors, calcium channel blockers, etc. (see e.g.
JM Bright, Prod 7th ACVIM, Chicago (1999), pp 134-135). Other treatments are mentioned by Brown, Scott A: Evaluation of chronic renal disease: A staged approach. Compendium on Continuing Education for the Practicing
Veterinarian Vol 21: 752-763, 1999.
With regard to chronic renal failure associated with hypertension, treatment with amlodipine has been propounded, e.g. by: Henik et al in J.Am.Animal Hosp. Assoc. May/June 1997, vol.33);
PS Snyder, in J. Vet.lntern. Med.(1998): 12:157;
KL Cooke et al, in J Vet. Intern. Med. (1998); 12:123;
GP Reams et al, Am.J.Kidney Diseases (Dec 1987), vol X no.6, 446; www.ccweb.net/marvistavet/html/body/chronic_renal_failure.html; and CJ Pearce et al, New Horizons (1996) vol.4 no.1) 123.
Amlodipine, disclosed in EP 0 089 167, etc., is a dihydropyridine calcium channel blocker which is licensed for use as an antihypertensive and antianginal agent. It is sold as the besylate salt (disclosed in EP 0 244 944, etc.) in 2.5mg, 5mg and 10mg dosages under the trade names Norvasc, Norvas, Istin, Amlor, etc. by Pfizer Inc. and related companies. Both of these publications are herein incorporated by reference.
We have now surprisingly found that calcium channel blockers such as amlodipine (e.g. as the besylate salt) can be used to treat renal disease in animals which are not hypertensive, i.e. animals which are "normotensive". "Normotensive" means having systemic arterial blood pressure values within normal or reference ranges established for the animal species of interest, using acceptable methods for measuring such blood pressure under appropriate circumstances, and below generally accepted "hypertensive" ranges for such animals. Within an animal species, reference range values may be established for representative subclasses, races, breeds, etc. (e.g. humans, lab. animals, specific subpopulations, etc.).
The prior art does not disclose or suggest that renal disease in normotensive patients, especially normotensive companion animals such as cats, can be treated with a calcium channel blocker such as amlodipine. An aspect of the current invention is the treatment of renal disease in normotensive animals with a calcium channel blocker.
Preferably the animal is a mammal. A preferred mammal is a human.
Another preferred group of mammals are companion animals such as horses, and domestic cats and dogs. The most preferred companion animal is a domestic cat.
Preferably the renal disease is chronic renal failure.
Preferably the calcium channel blocker is a dihydropyridine calcium channel blocker such as amlodipine, nifedipine, nitrendipine, nimodipine, nicardipine, felodipine, etc.
The calcium channel blocker can be present as a pharmaceutically acceptable salt or solvate thereof. Pharmaceutically acceptable salts and solvates are non-toxic to the species being treated. Suitable pharmaceutically acceptable salts for dihydropyridine calcium channel blockers include acid addition salts such as the hydrochloride, hydrobromide, hydroiodide, bisulphate, acid citrate, bitartrate, ethansulphonate, sulphate, phosphate or acid phosphate, acetate, maleate, fumarate, lactate, tartrate, citrate, gluconate, benzenesulphonate (besylate), p-toluenesulphonate (tosylate), methanesulphonate (mesylate), succinate, salicylate, nitrate, etc. More preferably the calcium channel blocker is amlodipine and the pharmaceutically acceptable salts thereof, including acid addition salts such as the hydrochloride, hydrobromide, hydroiodide, bisulphate, acid citrate, bitartrate, ethansulphonate, sulphate, phosphate or acid phosphate, acetate, maleate, fumarate, lactate, tartrate, citrate, gluconate, benzenesulphonate (besylate), p-toluenesulphonate (tosylate), methanesulphonate (mesylate), succinate, salicylate, nitrate, etc.
Most preferred is the amlodipine besylate salt.
"Pharmaceutically acceptable" and related phrases mentioned herein include the corresponding veterinary equivalents.
"Treatment" refers to prevention, alleviation and/or cure of the condition.
Another aspect of the invention is the administration, to a normotensive animal, of an efficacious amount of a calcium channel blocker, such as between 0.01 to 3mg/kg, preferably between 0.1mg/kg and 0.3mg/kg, more preferably between 0.12 and 0.25 mg/kg, amlodipine (preferably administered as the besylate salt) of the animal to treat renal disease such as chronic renal failure.
Another aspect of the invention is a unit dosage form of amlodipine which comprises about 0.1-1.5 mg, preferably about 0.2-0.6, or about 0.8 to 1.5 mg, most preferably about 0.1 , 0.2, 0.4, 0.6, 0.8, 1.0, 1.2 or 1.5mg amlodipine per unit, where amlodipine is preferably present as its besylate salt, suitable for, or adapted for, the treatment of normotensive cats with renal disease, such as chronic renal failure. Such unit doses can also be used to treat-renal disease in animals with hypertension. Optionally the calcium channel blocker can be administered / formulated with an antihypertensive agent of a different class (i.e. not another calcium channel blocker) such as an agent which reduces the effect of angiotensin and/or endothelin (defined herein as "other active agents"). Suitable agents include angiotensin converting enzyme (ACE) inhibitors such as those licensed for use in treating hypertension, such as benazepril, benazeprilat, captopril, enalapril, enalaprilat, fosinopril sodium, lisinopril, pentopril, perindopril, quinapril hydrochloride, quinaprilat, ramipril. ramiprilat, trandolapril, zofenopril calcium, and the like. Certain combinations of calcium channel blockers and ACE inhibitors are disclosed in International Patent Application publication no. WO 96/28185, which is herein incorporated by reference.
For such combination therapies, co-administration may take place in a number of different ways, including: the active agents may be present in the same dosage form for single administration; the active agents may be administered in separate dosage forms, by the same or different administration routes, and at the same, substantially the same or at different times. A suitable ACE inhibitor for co-administration in the treatment of renal disease is thought to be benazepril, currently marketed as Fortekor™, which for cats is administered at about 0.5 to about 1 mg/kg per day for cats as a 2.5mg or 5mg dose.
The calcium channel blockers (and/or other active agents) can be administered alone but will generally be administered in admixture with a suitable pharmaceutical excipient, diluent or carrier selected with regard to the intended route of administration and standard pharmaceutical or veterinary practice. Suitable pharmaceutical carriers, excipents, diluents, etc. can be found in Remington's Pharmaceutical Science, A. Osol, a standard reference text in the field. For example, the calcium channel blocker (and/or other active agents) can be administered orally, buccally or sublingually in the form of tablets, capsules, ovules, elixirs, syrups, boluses, powders, pastes, drenches , medicated food or drinking water or other liquid, solutions or suspensions, which may contain flavouring or colouring agents, for immediate-, delayed-, modified-, sustained-, pulsed- or controlled-release applications.
Such tablets may contain excipients such as microcrystalline cellulose, silicified microcrystalline cellulose, lactose, sodium citrate, calcium carbonate, dibasic calcium phosphate and glycine, disintegrants such as starch (optionally pre-gelatinised, preferably corn, potato or tapioca starch), sodium starch glycollate, croscarmellose sodium and certain complex silicates, and granulation binders such as polyvinylpyrrolidone, hydroxypropylmethylcellulose (HPMC), hydroxypropylcellulose (HPC), sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, stearic acid, glyceryl behenate and talc may be included. Additionally cyclodextrin solublity modifiers may be included. Additionally antioxidants may be included. Agents to improve palatability, such as flavouring agents (e.g. yeast, yeast extract, pork liver) may also be included. The agents apart from the calcium channel blocker may be present in intimate mixture with the calcium channel blocker, or they may be separated, e.g. in a bilayer, trilayer or other multlayer tablet or coated tablet, or a microparticulate capsule.
Solid compositions of a similar type may also be employed as fillers in gelatin capsules. Preferred excipients in this regard include lactose, starch, a cellulose, milk sugar or high molecular weight polyethylene glycols. For aqueous suspensions and/or elixirs, the calcium channel blockers (and/or other active agents) may be combined with various sweetening or flavouring agents, colouring matter or dyes, with emulsifying and/or suspending agents and with diluents such as water, ethanol, propylene glycol and glycerin, and combinations thereof.
The calcium channel blockers (and/or other active agents) can also be administered parenterally, for example, intravenously, intra-arterially, intraperitoneally, intrathecally, intraventricularly, intraurethrally, intrasternally, intracranially, intramuscularly or subcutaneously, or they may be administered by infusion techniques. For such parenteral administration they are best used in the form of a sterile aqueous solution, or sterile aqueous or oil suspension, which may contain other substances, for example, enough salts or glucose to make the solution isotonic with blood. The aqueous solutions should be suitably buffered (preferably to a pH of from 3 to 9), if necessary. The preparation of suitable parenteral formulations under sterile conditions is readily accomplished by standard pharmaceutical techniques well-known to those skilled in the art.
The calcium channel blockers (and/or other active agents) can also be administered intranasally or by inhalation and are conveniently delivered in the form of a dry powder inhaler or an aerosol spray presentation from a pressurised container, pump, spray or nebuliser with the use of a suitable propellant, e.g. dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, a hydrofluoroalkane such as 1 ,1,1 ,2- tetrafluoroethane (HFA 134A [trade mark]) or 1,1,1,2,3,3,3- heptafluoropropane (HFA 227EA [trade mark]), carbon dioxide or other suitable gas. In the case of a pressurised aerosol, the dosage unit may be determined by providing a valve to deliver a metered amount. The pressurised container, pump, spray or nebuliser may contain a solution or suspension of the active compound, e.g. using a mixture of ethanol and the propellant as the solvent, which may additionally contain a lubricant, e.g. sorbitan trioleate. Capsules and cartridges (made, for example, from gelatin) for use in an inhaler or insufflator may be formulated to contain a powder mix of the compound and a suitable powder base such as lactose or starch.
Alternatively, the calcium channel blocker (and/or other active agents) can be administered in the form of a suppository or pessary, or may be applied topically in the form of a gel, a pour-on, spot-on, dip, spray, mousse, shampoo, collar or powder formulation, ear tag, hydrogel, lotion, solution, cream, gel, paste, patch, ointment or dusting powder. The calcium channel blockers (and/or other active agents) may also be dermally or transdermally administered, for example, by the use of a skin patch. They may also be administered by the pulmonary or rectal routes.
For application topically to the skin, the calcium channel blocker (and/or other active agents) can be formulated as a suitable ointment containing the active compound suspended or dissolved in, for example, a mixture with one or more of the following: mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene polyoxypropylene compound, emulsifying wax and water. Alternatively, they can be formulated as a suitable lotion or cream, suspended or dissolved in, for example, a mixture of one or more of the following: mineral oil, sorbitan monostearate, a polyethylene glycol, liquid paraffin, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2- octyldodecanol, benzyl alcohol and water.
As an alternative for treating animals, the compounds may be administered with the animal feedstuff and for this purpose a concentrated feed additive or premix may be prepared for mixing with the normal animal feed.
For treatment of companion animals, further delivery devices are envisioned within the scope of this invention, such as the "chew" or masticable foπηulations mentioned in GB Patent application nos. 0007112.6 and 0010846.4, and the references therein. These formulations include: an oral formulation for a medicament comprising: a solid masticable portion and one or more reservoir portions encompassed by said solid masticable portion; the solid masticable portion consisting of a fully edible material, having a Young's modulus of 0.01-5MPa, and compressive strength in the range 10- 10,000 mJ, the reservoir portion or portions comprising a releasable dose of the medicament in a fluid (preferably a liquid) form, with a viscosity below 800mPa.s at body temperature (ca. 36-ca.40°C), such that on mastication, the masticable portion is ruptured and the unit dose of the medicament is released in a short space of time from the reservoir portion into the oral cavity.
The calcium channel blockers (and/or other active agents mentioned above) can also be administered together with yet further active agents should the medical need arise.
The physician or veterinarian in any event will determine the actual dosage which will be most suitable for any individual patient and it will vary with the age, weight and response of the particular patient. The dosages mentioned herein are exemplary of the average case. There can, of course, be individual instances where higher or lower dosage ranges are merited and such are within the scope of this invention. The skilled person will appreciate that, in the treatment of certain conditions the compounds may be taken as a single or multiple dose as needed or desired.
The route of administration will depend on a number of factors, and in accordance with standard medical and veterinary practice, including the species of animal to be treated, size of the animal, ease of administration, etc. Based on the results disclosed herein, the envisioned dosage regime for amlodipine in the treatment of renal disease, such as chronic renal failure, in normotensive animals, is 0.125-0.25mg/kg/day. For the treatment of renal disease in normotensive (and hypertensive) domestic cats the envisioned amlodipine dosage regime is 0.125 - 0.25 mg/kg / day, which translates to 0.4mg/cat/day for cats weighing from 1.6kg up to about 3kg, 0.8mg/cat/day for cats weighing between 3-6.5kg, and 1.2mg/cat/day for cats weighing about 6.5-9.5kg. Cats falling outside these weight ranges will of course be treatable in proportion to their weight. Oral administration is preferred, preferably of a tablet.
Benazepril may be co-administered at 0.5 to 1 mg/kg per day, e.g. as a 2.5mg or 5mg dose for domestic cats (as in Fortekor™ mentioned above). Other ACE inhibitors and/or endothelin-reducing agents may be co- administered with the calcium channel blocker such as amlodipine according to the medical need, efficacy, etc.
The efficacy of calcium channel blockers such as amlodipine in the treatment of chronic renal failure, in the dosages mentioned and with the populations mentioned can be demonstrated by measurement of renal function (e.g. by GFR measurements or any other measurements known in the art such as renal plasma flow using appropriate markers such as creatinine, inulin, iohexol, radioisotopes and other validated markers of dynamic renal function, urine concentrations of analytes such as protein and/or protein indexed to urine creatinine concentration, etc.). Measurements can be made before treatment, during treatment and after treatment by methods well-known in the art. For control purposes, a similar population can be treated with a placebo instead of a calcium channel blocker. Efficacy studies should be appropriately controlled for concurrent disease conditions, drug treatments, diet etc. that may confound the interpretation of data used to assess treatment of renal failure, and appropriate statistical analyses applied to variables. For measurement of blood pressure, e.g. to define the normotensive subpopulation, there are numerous methods mentioned in the art, such as that disclosed by PS Snyder, in J. Vet.lntern. Med.(1998): 12:157. Henik (supra) defines hypertension in cats as a blood pressure of 170mm Hg or more. Some other workers in the field define the level at 175mm Hg or more. Biological data - Example 1
In this experiment, comparative groups of normotensive nephrectomised cats with chronic renal failure had their GFR measured. One group received placebo and the other received amlodipine besylate once daily at 0.125mg/kg. After 35 days the GFR was measured again. There was no change in the placebo group, but the GFR had increased by an average of ca. 28% for the amlodipine-treated group.
Amlodipine besylate at ca. 0.125 mg/kg to ca. 0.25 mg/kg was administered orally by tablet (0.2 mg, 0.4 mg, 0.8 mg and 1.2mg) to normotensive cats (systolic blood pressure of 160mm Hg or less as measured under standard conditions) once daily for a number of weeks, and measurements made at intervals to measure the effect on kidney function in cats presented as veterinary patients with renal problems. In parallel, a number of cats were treated with an oral placebo tablet. Various breeds and crossbreeds of cats of approximately 6 months of age or older were used in the trial. Initial weights of 0.8kg to 9.6 kg were chosen, and the cats were either males or non-pregnant females (entire or neutered). For each animal, the body weight was used to select the appropriate tablet potency of amlodipine (0.125 to 0.25 mg/kg/day) according to the following table:
Bodv Weiαht
Kilograms Pounds Tablet Potency
(kq) (lb) (mg) 0.8 to 1.5 1.8 to 3.5 0.2
1.6 to 3.0 3.6 to 7.0 0.4
3.1 to 6.5 7.1 to 14.0 0.8
6.6 to 9.5 14.1 to 21.0 0.8 + 0.4
Each of the amlodipine tablets used in the study were complemented by placebo tablets with the same excipients and which had the same dimensions and appearance.
Particular amlodipine besylate tablets used had the following compositions:
Figure imgf000013_0001
Figure imgf000013_0002
(1) Equivalent to 0.2 mg of amlodipine calculated on a theoretical activity of 72%.
Figure imgf000014_0001
Figure imgf000014_0002
(2) Equivalent to 0.4 mg of amlodipine calculated on a theoretical activity of 72%.
Figure imgf000014_0003
Figure imgf000015_0001
Figure imgf000015_0002
(3) Equivalent to 0.8 mg of amlodipine calculated on a theoretical activity of 72%.
The tablets were prepared using standard blending and direct compression techniques. The tablets described herein used the same excipients and manufacturing processes as the commercially available tablets.
Biological data - Experiment 2
The data in the Table below were collected from client-owned, pet cats that had been diagnosed with spontaneous chronic renal failure (chronic renal insufficiency). These cats were presented by owners/clients to veterinary practices for evaluation of general health, kidney function, and systolic blood pressure. Chronic renal failure is generally considered an irreversible and progressive disease in cats. Chronic renal failure was diagnosed in each cat in this study. Cats were considered normotensive as defined by systolic arterial blood pressure less than 160 mm Hg prior to the onset of treatment. Cats were randomly assigned to treatment with either amlodipine besylate tablets at 0.125 to 0.25 mg/kg (as described above) or placebo tablets administered once daily by the oral route.
Renal function was assessed by determining glomerular filtration rate (GFR). GFR was estimated from plasma clearance of the exogenous marker, iohexol, approximately 7 days prior to the onset of treatment (day -7) and on approximately days 28, 56, 112, and 224 following onset of treatment.
Table - Glomerular filtration rate (mL/min/kg) in cats with chronic renal failure treated once daily by the oral route with either amlodipine besylate at 0.125 to 0.25 mg/kg or placebo
Day of Study -7 28 56 112 224
Treatment
Amlodipine
Mean GFR 0.76 0.80 0.78 0.85 0.83
Std Deviation 0.29 0.36 0.26 0.31 0.26
Number of Cats 10 9 10 9 10
Placebo
Mean GFR 0.90 0.89 0.92 0.85 0.75
Std Deviation 0.23 0.22 0.22 0.23 0.30
Number of Cats 13 12 12 13 13
In cats receiving amlodipine, GFR increased on average 9% between day -7 and day 224. In contrast, placebo-treated animals experienced a decline in GFR of 17% between day -7 and day 224. These data demonstrate that amlodipine besylate at 0.125 to 0.25 mg/kg/day orally prevents the decline in function associated with the progression of chronic renal failure in cats.
Examples of formulations offering 0.4mg and 0.8mg amlodipine respectively, based on a potency of 72.1%, which demonstrated robustness and good stability are described below. These were made by standard direct compression techniques well known in the art.
Figure imgf000017_0001
Figure imgf000017_0002
Footnotes:
(a) Equivalent to 0.4mg/tablet of based on a potency of 72.1 % (b) As Avicel PH102™
(c) As Explotab CLV™
(d) As Debittered brewers yeast 1330
(e) Equivalent to 0.8mg/tablet of based on a potency of 72.1%

Claims

1. The use of a calcium channel blocker optionally in the presence of a antihypertensive agent of a different class, such as an agent that reduces the effect of endothelin and/or angiotensin, in the manufacture of a medicament for the treatment of chronic renal failure in normotensive animals.
2. The use according to claim 1 wherein the calcium channel blocker is a dihydropyridine.
3. The use according to any previous claim wherein the calcium channel blocker is amlodipine.
4. The use according to any previous claim wherein the calcium channel blocker is amlodipine besylate.
5. A method of treating renal disease in normotensive animals comprising administration of an effective amount of a calcium channel blocker, optionally in the presence of an antihypertensive agent of a different class, such as an agent that reduces the effect of endothelin and/or angiotensin.
6. The method according to claim 5 wherein wherein the calcium channel blocker is a dihydropyridine.
7. The method according to any of claims 6 or 7 wherein the calcium channel blocker is amlodipine.
8. The method according to one of claims 5, 6 or 7 wherein the calcium channel blocker is amlodipine besylate.
9. A unit dosage form of amlodipine comprising amlodipine at about 0.1-0.4, or about 0.8 to 1.5 mg, most preferably about 0.1 , 0.2, 0.4, 0.8, 1.0, 1.2 or
1.5mg amlodipine per unit, preferably with amlodipine present as the besylate salt, optionally in the presence of an antihypertensive agent such as an agent that reduces the effect of endothelin and/or angiotensin, and a pharmaceutical or veterinary carrier, diluent or adjuvant, and which is suitable for the treatment of a companion animal such as a domestic cat.
10. A unit dosage form according to claim 9 wherein the available amlodipine is present at about 0.4mg or O.δmg per unit.
11. A pack comprising a formulation of a calcium channel blocker, optionally in the presence of a hypertensive agent of a different class, such as an agent that reduces the effect of endothelin and/or angiotensin, and a pharmaceutical or veterinary carrier, diluent or adjuvant, suitable for the treatment of a companion animal such as a domestic cat, and instructions describing the treatment of renal disease in normotensive animals.
PCT/IB2001/000518 2000-04-04 2001-03-28 The use of a calcium channel blocker for treating renal disorders WO2001074390A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
MXPA02009819A MXPA02009819A (en) 2000-04-04 2001-03-28 Treatment of renal disorders.
BR0109783-0A BR0109783A (en) 2000-04-04 2001-03-28 Treatment of kidney disease
EP01914134A EP1284719A2 (en) 2000-04-04 2001-03-28 The use of a calcium channel blocker for treating renal disorders
JP2001572132A JP2003528927A (en) 2000-04-04 2001-03-28 Treatment of renal dysfunction
CA002403950A CA2403950A1 (en) 2000-04-04 2001-03-28 Treatment of renal disorders
AU2001239510A AU2001239510A1 (en) 2000-04-04 2001-03-28 Treatment of renal disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0008332.9A GB0008332D0 (en) 2000-04-04 2000-04-04 Treament
GB0008332.9 2000-04-04

Publications (2)

Publication Number Publication Date
WO2001074390A2 true WO2001074390A2 (en) 2001-10-11
WO2001074390A3 WO2001074390A3 (en) 2002-05-30

Family

ID=9889228

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2001/000518 WO2001074390A2 (en) 2000-04-04 2001-03-28 The use of a calcium channel blocker for treating renal disorders

Country Status (12)

Country Link
EP (1) EP1284719A2 (en)
JP (1) JP2003528927A (en)
AR (1) AR027763A1 (en)
AU (1) AU2001239510A1 (en)
BR (1) BR0109783A (en)
CA (1) CA2403950A1 (en)
GB (1) GB0008332D0 (en)
MX (1) MXPA02009819A (en)
PA (1) PA8514601A1 (en)
PE (1) PE20011163A1 (en)
TN (1) TNSN01051A1 (en)
WO (1) WO2001074390A2 (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002053134A1 (en) * 2000-12-29 2002-07-11 Pfizer Limited Pharmaceutical compositions comprising amlodipine maleate
WO2002053135A1 (en) * 2000-12-29 2002-07-11 Pfizer Limited Amlodipine free base
WO2003039530A1 (en) * 2001-11-07 2003-05-15 Synthon B.V. Tamsulosin tablets
NL1019882C2 (en) * 2002-02-01 2003-08-04 Synthon Licensing Pharmaceutical tablet composition useful for treating or preventing hypertension, angina or congestive heart failure comprises amlodipine free base
WO2004028566A1 (en) * 2002-09-30 2004-04-08 Kowa Company, Ltd. Pharmaceutical composition for prevention and treatment of kidney diseases
JP2005526756A (en) * 2002-03-11 2005-09-08 ノバルティス アクチエンゲゼルシャフト Taste masked solid veterinary composition
WO2006085208A2 (en) * 2005-02-11 2006-08-17 Ranbaxy Laboratories Limited Stable solid dosage forms of amlodipine and benazepril
US7335380B2 (en) 2000-12-29 2008-02-26 Synthon Ip Inc. Amlodipine free base
EP3045174A1 (en) 2003-01-31 2016-07-20 Daiichi Sankyo Company, Limited Medicine for prevention of and treatment for arteriosclerosis and hypertension
US10130624B2 (en) 2005-03-15 2018-11-20 Lupin Limited Pharmaceutical compositions of amlodipine and benazepril

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2398447C2 (en) * 2005-04-29 2010-09-10 Хилл'С Пет Ньютришн, Инк. Methods for prolongation of cats' lives
WO2017164208A1 (en) * 2016-03-24 2017-09-28 第一三共株式会社 Medicine for treating renal disease

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0290211A1 (en) * 1987-05-02 1988-11-09 Pfizer Limited Dihydropyridines
EP0459666A2 (en) * 1990-05-31 1991-12-04 Pfizer Inc. Medicaments against impotence
WO1992020342A1 (en) * 1991-05-15 1992-11-26 E.I. Du Pont De Nemours And Company Novel composition of angiotensin-ii receptor antagonists and calcium channel blockers
WO1993010779A1 (en) * 1991-11-26 1993-06-10 Sepracor, Inc. Methods and compositions for treating hypertension, angina and other disorders using optically pure (-) amlodipine
WO1996028185A2 (en) * 1995-03-16 1996-09-19 Pfizer Inc. Composition containing amlodipine, or a salt, or felodipine and an ace inhibitor
EP0795327A1 (en) * 1996-03-13 1997-09-17 Pfizer Inc. Use of Amlodipine for the treatment and prophylaxis of congestive cardiac failure of non-ischaemic origin

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0290211A1 (en) * 1987-05-02 1988-11-09 Pfizer Limited Dihydropyridines
EP0459666A2 (en) * 1990-05-31 1991-12-04 Pfizer Inc. Medicaments against impotence
WO1992020342A1 (en) * 1991-05-15 1992-11-26 E.I. Du Pont De Nemours And Company Novel composition of angiotensin-ii receptor antagonists and calcium channel blockers
WO1993010779A1 (en) * 1991-11-26 1993-06-10 Sepracor, Inc. Methods and compositions for treating hypertension, angina and other disorders using optically pure (-) amlodipine
WO1996028185A2 (en) * 1995-03-16 1996-09-19 Pfizer Inc. Composition containing amlodipine, or a salt, or felodipine and an ace inhibitor
EP0795327A1 (en) * 1996-03-13 1997-09-17 Pfizer Inc. Use of Amlodipine for the treatment and prophylaxis of congestive cardiac failure of non-ischaemic origin

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
PARFITT K.: "Martindale -The complete drug reference" 1999 , PHARMACEUTICAL PRESS , LONDON, UK XP002184526 page 822 -page 823 *
RAMAN G VENKAT ET AL: "Renal effects of amlodipine in normotensive renal transplant recipients" NEPHROLOGY DIALYSIS TRANSPLANTATION, vol. 14, no. 2, 1999, pages 384-388, XP001041763 ISSN: 0931-0509 *
RAMAN G.V. ET AL: "Modifying effects of amlidipine on cyclosporin A-induced changes in renal function in patients with psoriasis" JOURNAL OF HYPERTENSION, vol. 16, no. suppl. 4, 1998, pages S39-S41, XP001041741 *
SNYDER P.S. ET AL.: "Evaluation of the antihypertensive agent amlodipine besylate innormotensive cats and a cat with systemic hypertension." JOURNAL OF VETERINARY INTERNAL MEDICINE, vol. 8, 1994, page 147 XP001042122 cited in the application *
SNYDER P.S.: "Amlodipine: a randomized, blinded clinical trial in 9 cats with systemic hypertension" J. VET. INTERN. MED. , vol. 12, 1998, pages 157-162, XP001041936 cited in the application *
TOBLLI JORGE EDUARDO ET AL: "Effects of amlodipine on tubulointerstitial lesions in normotensive hyperoxaluric rats." HYPERTENSION (BALTIMORE), vol. 34, no. 4 PART 2, October 1999 (1999-10), pages 854-858, XP001041746 ISSN: 0194-911X *

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002053135A1 (en) * 2000-12-29 2002-07-11 Pfizer Limited Amlodipine free base
WO2002053134A1 (en) * 2000-12-29 2002-07-11 Pfizer Limited Pharmaceutical compositions comprising amlodipine maleate
US7335380B2 (en) 2000-12-29 2008-02-26 Synthon Ip Inc. Amlodipine free base
EA008101B1 (en) * 2000-12-29 2007-04-27 Пфайзер Лимитед Pharmaceutical compositions comprising amlodipine maleate
CN1298317C (en) * 2001-11-07 2007-02-07 斯索恩有限公司 Tamsulosin tablets
WO2003039530A1 (en) * 2001-11-07 2003-05-15 Synthon B.V. Tamsulosin tablets
NL1021822C2 (en) * 2001-11-07 2003-07-15 Synthon Bv Tamsulosin tablets.
JP2005512997A (en) * 2001-11-07 2005-05-12 シントン・ベスローテン・フェンノートシャップ Tamsulosin tablets
NL1019882C2 (en) * 2002-02-01 2003-08-04 Synthon Licensing Pharmaceutical tablet composition useful for treating or preventing hypertension, angina or congestive heart failure comprises amlodipine free base
JP2005526756A (en) * 2002-03-11 2005-09-08 ノバルティス アクチエンゲゼルシャフト Taste masked solid veterinary composition
US8617587B2 (en) 2002-03-11 2013-12-31 Novartis Ag Tasted masked veterinary solid compositions
WO2004028566A1 (en) * 2002-09-30 2004-04-08 Kowa Company, Ltd. Pharmaceutical composition for prevention and treatment of kidney diseases
US7423009B2 (en) 2002-09-30 2008-09-09 Kowa Company, Ltd. Method for treatment of kidney diseases
EP3045174A1 (en) 2003-01-31 2016-07-20 Daiichi Sankyo Company, Limited Medicine for prevention of and treatment for arteriosclerosis and hypertension
WO2006085208A3 (en) * 2005-02-11 2006-10-19 Ranbaxy Lab Ltd Stable solid dosage forms of amlodipine and benazepril
WO2006085208A2 (en) * 2005-02-11 2006-08-17 Ranbaxy Laboratories Limited Stable solid dosage forms of amlodipine and benazepril
US10130624B2 (en) 2005-03-15 2018-11-20 Lupin Limited Pharmaceutical compositions of amlodipine and benazepril

Also Published As

Publication number Publication date
AU2001239510A1 (en) 2001-10-15
PE20011163A1 (en) 2001-11-12
AR027763A1 (en) 2003-04-09
EP1284719A2 (en) 2003-02-26
BR0109783A (en) 2003-01-21
WO2001074390A3 (en) 2002-05-30
JP2003528927A (en) 2003-09-30
GB0008332D0 (en) 2000-05-24
CA2403950A1 (en) 2001-10-11
PA8514601A1 (en) 2002-08-26
MXPA02009819A (en) 2003-03-27
TNSN01051A1 (en) 2005-11-10

Similar Documents

Publication Publication Date Title
US6521647B2 (en) Treatment of renal disorders
CN109568253B (en) Liquid preparation
Clarke et al. Medetomidine, a new sedative‐analgesic for use in the dog and its reversal with atipamezole
TWI415605B (en) Angiotensin ii receptor antagonist for the prevention or treatment of systemic diseases in cats
KR101667081B1 (en) Solid pharmaceutical fixed dose compositions comprising irbesartan and amlodipine, their preparation and their therapeutic application
WO2001074390A2 (en) The use of a calcium channel blocker for treating renal disorders
US20100267693A1 (en) Orodispersible pharmaceutical composition of ivabradine
ES2374399T3 (en) PIRIDOXAMINE FOR USE IN THE TREATMENT OF DIABETIC NEPHROPATHY IN TYPE II DIABETES.
JP2020523334A (en) Vibegron dosing for the treatment of overactive bladder
Weller et al. Psychotropic drugs and alcohol: Pharmacokinetic and pharmaco dynamic interactions
JP2019076007A (en) Pet supplement, drinking water for pet, pet food, food additive for pet, in-blood urea nitrogen increase depressor for pet and pharmaceutical composition for pet, and method for suppressing increase of in-blood urea nitrogen of pet
RU2182002C2 (en) Composition containing fixed dose of angiotensin-transforming enzyme and calcium canal antagonist and method for producing the composition and treating cardiovascular diseases
AU2016239689B2 (en) Oral solid dosage form of amlodipine and veterinary uses thereof
US20050089558A1 (en) Compositions and methods for the co-formulation and administration of tramadol and propoxyphene
MX2013013124A (en) Combinations of trospium and salivary stimulants for the treatment of overactive bladder.
Medoxomil et al. PrACT OLMESARTAN
TW202010496A (en) Pharmaceutical preparations of sebacoyl dinalbuphine and acetaminophen and methods for treating pain
Crome et al. Pharmacokinetics of tricyclic and related antidepressants

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2001914134

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2403950

Country of ref document: CA

ENP Entry into the national phase in:

Ref country code: JP

Ref document number: 2001 572132

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/009819

Country of ref document: MX

WWP Wipo information: published in national office

Ref document number: 2001914134

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001914134

Country of ref document: EP